Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A Murine tumor model

Vaccine

Volumn 15, Issue 4, 1997, Pages 387-394

  Carroll, Miles W ^a   Overwijk, Willem W ^b   Chamberlain, Ronald S ^b   Rosenberg, Steven A ^b   Moss, Bernard ^a   Restifo, Nicholas P ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cancer immunotherapy; modified vaccinia virus Ankara (MVA); vaccinia virus

Indexed keywords

CANCER VACCINE; RECOMBINANT VACCINE; TUMOR ANTIGEN; VACCINIA VACCINE;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS;

ADENOCARCINOMA; ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BETA-GALACTOSIDASE; CANCER VACCINES; COLONIC NEOPLASMS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; IMMUNIZATION, SECONDARY; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; SPLEEN; TUMOR CELLS, CULTURED; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 0031004055     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00195-8     Document Type: Article

References (48)

1. Boon, T., Gajewski, T.F. and Coulie, P.G. From defined human tumour antigens to effective immunization? Immunol. Today 1995, 16, 334-336
2. Boon, T., Cerottini, J., Van den Eynde, B., van der Bruggen, P. and Van Pel, A. Tumour antigens recognized by T lymphocytes. A. Rev. Immunol. 1994, 12, 337-365
3. Rosenberg, S.A. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J. 1995, 1, 90-100
4. Arita, I. Virological evidence for the success of the smallpox eradication programme. Nature 1979, 279, 293-298
5. Mackett, M., Smith, G.L. and Moss, B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc. Natl Acad. Sci. USA 1982, 79, 7415-7419
6. Panicali, D. and Paoletti, E. Construction of poxviruses as cloning vectors: insertion of the TK gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl Acad. Sci. USA 1982, 79, 4927-4931
7. Kantor, J., Irvine, K., Abrams, S., Kaufman, H., DiPietro, J. and Schlom, J. Antitumour activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl Cancer Inst. 1992, 84, 1084-1091
8. Estin, C.D., Stevenson, U.S. and Plowman, G.D. et al. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc. Natl Acad. Sci. USA 1988, 85, 1052-1056
9. Roth, J., Dittmer, D., Rea, D., Tartaglia, L., Paoletti, E. and Levine, A.J. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumour cell challenge. Proc. Natl Acad. Sci. USA 1996, 93, 4781-4786
10. Meneguzzi, G., Cemi, C., Kieny, M.P. and Lathe, R. Immunization against human papillomavirus type 16 tumour cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991, 181, 62-69
11. Lathe, R., Kieny, M.P. and Gerlinger, P. et al. Tumour prevention and rejection with recombinant vaccinia. Nature 1987, 326, 878-880
12. Manhel, H. and Mayr, A. Erfahrungen bei der Schutzimpfung gegen orthopocken von mensch und tier mit dem impfstamm MVA. Berlin. München, tierärztliche wochenschrift 1994, 107, 253-256
13. Mayr, A., Hochstein-Mintzel, V. and Stickl, H. Abstammung, eigenschaften und verwendung des attenuierten vacciniastammes MVA. Infection 1975, 3, 6-14
14. Sutter, G. and Moss, B. Nonreplicating vaccinia virus vector efficiently expresses recombinant genes. Proc. Natl Acad. Sci. USA 1992, 89, 10847-10851
15. Smith, G.L. and Moss, B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 1983, 25, 21-28
16. Sutter, G., Wyatt, L., Foley, P., Bennink, J.R. and Moss, B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12, 1032-1040
17. Moss, B., Carroll, M.W., Wyatt, L.S. et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. In: Novel Strategies in the Design and Production of Vaccines (Proceedings of the 39th Oholo conference) (Eds Cohen, S. and Shafferman, A.). Plenum Publishing Corporation, New York, 1996, pp. 7-13
18. Hirsch, V.N., Fuerst, T.R. and Suiter, G. et al. Patterns of viral replication correllate with outcome in simian immunodeficiency virus-infected macaques: effects prior to immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara (MVA). J. Virol. 1996, 70, 3741-3752
19. Wang, M., Bronte, V. and Chen, P.W. et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumour-associated antigen. J. Immunol. 1995, 154, 4685-4692
20. Bronte, V., Tsung, K. and Rao, J.B. et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 1995, 154, 5282-5292
21. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C.C. p53 mutalions in human cancers. Science 1991, 253, 49
22. Townsend, A., Ohlen, C., Rogers, M., Edwards, J., Mukhedee, S. and Bastin, J. Source of unique tumour antigens. Nature 1994, 371, 662
23. Beverley, P.C., Sadovnikova, E., Zhu, X. et al. Strategies for studying mouse and human immune responses to human papillomavirus type 16. In: Vaccines Against Virally Induced Cancers. Wiley, Chichester, UK, 1994, pp. 78-96
24. Milich, D.R., Jones, J., Hughes, J. and Maruyama, T. Hepatitis B virus infection, the immune response and hepatocellular carcinoma. In: Vaccines Against Virally Induced Cancers. Wiley, Chichester, UK, 1994, pp. 113-131
25. Moss, D.J., Burrows, S.R., Suhrbier, A. and Khanna, R. Potential antigenic targets on Epstein-Barr virus-associated tumours and the host response. In: Vaccines Against Virally Induced Cancers. Wiley, Chichester, UK, 1994, pp. 1-20
26. de The, G., Bomford, R., Kazanji, M. and Ibrahim, F. Human T cell lymphotropic virus: necessity for and feasibility of a vaccine. In: Vaccines Against Virally Induced Cancers. Wiley, Chichester, UK, 1994, pp. 47-60
27. Brattain, M.G., Strobel-Stevens, J., Fine, D., Webb, M. and Sarrif, A.M. Establishment of mouse colonic carcinoma cell lines with different metastalic properties. Cancer Res. 1980, 40, 2142-2146
28. Meyer, H., Sutter, G. and Mayr, A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 1991, 72, 1031-1038
29. Weir, J.P. and Moss, B. Determination of the promoter region of an early vaccinia virus gene encoding thymidine kinase. Virology 1987, 158, 206-210
30. Rosel, J.L., Earl, PL., Weir, J.P. and Moss, B. Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the Hind III H genome fragment. J. Virol. 1986, 60, 436-449
31. Earl, P.L., Cooper, N. and Moss, B. Preparation of cell cultures and vaccinia virus stocks. In: Current Protocols in Molecular Biology (Eds Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G. and Smith, L.A.). Greene Publishing Associates and Wiley Interscience, New York, 1991, pp. 16.16.1-16.16.17
32. Irvine, K.R., McCabe, B.J., Rosenberg, S.A. and Restifo, N.P. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J. Immunol. 1995, 154, 4651-4657
33. Kaplan and Meier. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 53, 457-481
34. Wang, M., Chen, P.W., Bronte, V., Rosenberg, S.A. and Restifo, N.P. Anti-tumour activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumour associated antigen. J. Immunother. 1995, 18, 139-146
35. Rooney, J.F., Wohlenberg, C.R., Cremer, K.J., Moss, B. and Notkins, A.L. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type I glycoprotein D: longterm protection and effect of revaccination. J. Virol. 1988, 62, 1530-1534
36. Kundig, T.M., Kalberer, C.P., Hengartner, H., Zinkernagel, R.M. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 1993, 11, 1154-1158
37. Cooney, E.L., Collier, A.C. and Greenberg, P.D. et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991, 337, 567-572
38. Coupar, B.E.H., Andrew, M.E., Both, G.W. and Boyle, D.B. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur. J. Immunol. 1986, 16, 1479-1487
39. Symons, J.A., Alcami, A. and Smith, G.L. Vaccinia virus encodes a soluble type l interferon receptor of novel structure and broad species specificity. Cell 1995, 81, 551-560
40. Alcami, A. and Smith, G.L. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J. Virol. 1995, 69, 4633-4639
41. Alcami, A. and Smith, G.L. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 1992, 71, 153-167
42. Smith, G.L. Vaccinia virus glycoproteins and immune evasion. The sixteenth Fleming Lecture. J. Gen. Virol. 1993, 74, 1725-1740
43. McFadden, G. Viroceptors, Virokines and Related Immune Modulators Encoded by DNA Viruses. R.G. Landes Company, 1994
44. Zinkernagel, R.M. The role of antigen in maintaining T cell memory. Dev. Biol. Stand. 1994, 82, 189-191
45. Lau, L.L., Jamieson, B.D., Somasundaram, T. and Ahmed, R. Cytotoxic T-cell memory without antigen. Nature 1994, 369, 648-652
46. Lehmann, F., Marchand, M. and Hainaut, P. et al. Differences in the antigens recognized by cytoloytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 1995, 25, 340-347
47. Chen, L, Ashe, S., Singhal, M.C., Galloway, D.A., Hellstrom, I. and Hellstrom, K.E. Metastatic conversion of cells by expression of human papillomavirus type 16 E6 and E7 genes. Proc. Natl Acad. Sci. USA 1993, 90, 6523-6527
48. Somogyi, P., Frazier, J. and Skinner, M.A. Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology 1993, 197, 439-444